公开(公告)号：US20230365534A1

公开(公告)日：2023-11-16

申请号：US18316994

申请日：2023-05-12

Applicant: Neumora Therapeutics, Inc.

Inventor： Anne-Marie Beausoleil ,  Ryan Hudson

IPC: C07D403/12 ,  C07D403/14 ,  C07D407/12 ,  C07D237/20

CPC classification number: C07D403/12 ,  C07D403/14 ,  C07D407/12 ,  C07D237/20

Abstract: Compounds are provided for modulating NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):




or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein X, R1, R2, R3, R4, R5, R8, R9, R10, R1, R12, R13, and n are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

公开(公告)号：US20230343463A1

公开(公告)日：2023-10-26

申请号：US18311087

申请日：2023-05-02

Applicant: NEUMORA THERAPEUTICS, INC.

Inventor： Monika Sharma MELLEM ,  Yuelu LIU ,  Parvez AHAMMAD ,  Humberto Andres GONZALEZ CABEZAS ,  William J. MARTIN ,  Pablo Christian GERSBERG

IPC: G16H50/30 ,  G16H50/20 ,  G16H10/60

CPC classification number: G16H50/30 ,  G16H50/20 ,  G16H10/60

Abstract: Systems and methods for utilizing machine learning to generate a trans-diagnostic classifier that is operative to concurrently diagnose a plurality of different mental health disorders using a single trans-diagnostic questionnaire that includes a plurality of questions (e.g., 17 questions). Machine learning techniques are used to process labeled training data to build statistical models that include trans-diagnostic item-level questions as features to create a screen to classify groups of subjects as either healthy or as possibly having a mental health disorder. A subset of questions is selected from the multiple self-administered mental health questionnaires and used to autonomously screen subjects across multiple mental health disorders without physician involvement, optionally remotely and repeatedly, in a short amount of time.

公开(公告)号：US11798681B2

公开(公告)日：2023-10-24

申请号：US17960744

申请日：2022-10-05

Applicant: NEUMORA THERAPEUTICS, INC.

Inventor： Tathagata Banerjee ,  Matthew Edward Kollada

IPC: G16H40/20 ,  G16H50/70 ,  G16H50/20 ,  G06N3/02 ,  G06N3/045 ,  G06N3/08 ,  G16H30/40 ,  G06V10/77 ,  G06V10/82 ,  G06V10/774 ,  G06T7/00 ,  G06N20/00

CPC classification number: G16H40/20 ,  G06N3/02 ,  G06N3/045 ,  G06N3/08 ,  G06T7/0016 ,  G06V10/774 ,  G06V10/7715 ,  G06V10/82 ,  G16H30/40 ,  G16H50/20 ,  G16H50/70 ,  G06N20/00 ,  G06T2207/10088 ,  G06T2207/10104 ,  G06T2207/20081 ,  G06T2207/20084 ,  G06T2207/30016 ,  G06T2207/30104 ,  G06V2201/03

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for jointly training an encoder neural network and a decoder neural network. In one aspect, a method comprises: updating current values of a set of encoder parameters and current values of a set of decoder parameters using gradients of a reconstruction loss function that measures an error in a reconstruction of multi-modal data from a training example, wherein: the reconstruction loss function comprises a plurality of scaling factors that each scale a respective term in the reconstruction loss function that measures an error in the reconstruction of a corresponding proper subset of feature dimensions of the multi-modal data from the training example.

公开(公告)号：US20220392637A1

公开(公告)日：2022-12-08

申请号：US17740713

申请日：2022-05-10

Applicant: NEUMORA THERAPEUTICS, INC.

Inventor： Matthew Kollada ,  Tathagata Banerjee

IPC: G16H50/20 ,  G16H10/20

Abstract: Methods and systems are provided for diagnosing mental health conditions using multiple data modalities. In particular, a trained machine learning model is used for mental health diagnosis, wherein the trained model utilizes a dynamic fusion approach for capturing and preserving interactions as well as timing information between the multiple data modalities.

公开(公告)号：US12247037B2

公开(公告)日：2025-03-11

申请号：US17311974

申请日：2019-12-12

Applicant: Neumora Therapeutics, Inc.

Inventor： Gary Brandt

IPC: C07D519/00 ,  A61P25/22

Abstract: The present invention relates to 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds of Formula (I): wherein A, B, G, R1, R1b, RiC, R2 and X are as defined herein. The present compounds are vasopressin receptor antagonists (in particular of the Via receptor) for the treatment of neuro-psychological disorders, such as e.g. autism, anxiety, stress-related disorders, depression, schizophrenia or bipolar disorder. The present description discloses the synthesis of exemplary compounds, as well as pharmacological data thereof (e.g. pages 71 to 246; examples 1 to 49; tables 1 to 5). An exemplary compound is e.g. 8-chloro-1-(2-(5-fluoropyridin-2-yl)-2,6-diazaspiro[3.3]heptan-6-yl)-5-methyl-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (example 1, compound no. 1).

公开(公告)号：US20250074888A1

公开(公告)日：2025-03-06

申请号：US18724789

申请日：2022-12-28

Applicant: Neumora Therapeutics, Inc.

Inventor： Anne-Marie BEAUSOLEIL ,  Ryan HUDSON

IPC: C07D401/12 ,  A61K31/501 ,  A61K31/55 ,  C07D403/12

Abstract: Compounds are provided for modulating NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R11, R12, and R13 are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

公开(公告)号：US20240246928A1

公开(公告)日：2024-07-25

申请号：US18526960

申请日：2023-12-01

Applicant: NEUMORA THERAPEUTICS, INC.

Inventor： Paul Dransfield ,  Dilinie Fernando ,  James Harvey ,  Brian Sparling ,  John Stellwagen ,  Zhihua Ma ,  Anne-Marie Beausoleil ,  Ryan Hudson

IPC: C07D401/04

CPC classification number: C07D401/04

Abstract: The present disclosure relates to compounds of Formula (I),




and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.

公开(公告)号：US20240221950A1

公开(公告)日：2024-07-04

申请号：US18557873

申请日：2022-04-28

Applicant: NEUMORA THERAPEUTICS, INC.

Inventor： Matthew KOLLADA ,  Tathagata BANERJEE

IPC: G16H50/20 ,  A61B5/00 ,  G16H10/20

CPC classification number: G16H50/20 ,  A61B5/0077 ,  A61B5/4076 ,  A61B5/4842 ,  G16H10/20

Abstract: The disclosed technology is directed to improvements in multi-modal and multi-sensor diagnostic devices, that utilize machine learning algorithms to diagnose patients based on data from different sensor types and formats. Current machine learning algorithms that classify a patient's diagnosis focus on one modality of data output from one type of sensor or device. This is because, among other reasons, it is difficult determine which modalities or features from different modalities will be most important to a diagnosis, and also very difficult to identify an algorithm that can effectively to combine them to diagnose health disorders.

公开(公告)号：US12002590B2

公开(公告)日：2024-06-04

申请号：US18311087

申请日：2023-05-02

Applicant: NEUMORA THERAPEUTICS, INC.

Inventor： Monika Sharma Mellem ,  Yuelu Liu ,  Parvez Ahammad ,  Humberto Andres Gonzalez Cabezas ,  William J. Martin ,  Pablo Christian Gersberg

IPC: G16H50/30 ,  G16H10/60 ,  G16H50/20

CPC classification number: G16H50/30 ,  G16H10/60 ,  G16H50/20

Abstract: Systems and methods for utilizing machine learning to generate a trans-diagnostic classifier that is operative to concurrently diagnose a plurality of different mental health disorders using a single trans-diagnostic questionnaire that includes a plurality of questions (e.g., 17 questions). Machine learning techniques are used to process labeled training data to build statistical models that include trans-diagnostic item-level questions as features to create a screen to classify groups of subjects as either healthy or as possibly having a mental health disorder. A subset of questions is selected from the multiple self-administered mental health questionnaires and used to autonomously screen subjects across multiple mental health disorders without physician involvement, optionally remotely and repeatedly, in a short amount of time.

公开(公告)号：US20240136058A1

公开(公告)日：2024-04-25

申请号：US18542321

申请日：2023-12-15

Applicant: NEUMORA THERAPEUTICS, INC.

Inventor： Tathagata Banerjee ,  Matthew Edward Kollada

IPC: G16H40/20 ,  G06N3/02 ,  G06N3/045 ,  G06N3/08 ,  G06T7/00 ,  G06V10/77 ,  G06V10/774 ,  G06V10/82 ,  G16H30/40 ,  G16H50/20 ,  G16H50/70

CPC classification number: G16H40/20 ,  G06N3/02 ,  G06N3/045 ,  G06N3/08 ,  G06T7/0016 ,  G06V10/7715 ,  G06V10/774 ,  G06V10/82 ,  G16H30/40 ,  G16H50/20 ,  G16H50/70 ,  G06N20/00

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for jointly training an encoder neural network and a decoder neural network. In one aspect, a method comprises, for each latent dimension in a proper subset of a plurality of latent dimensions of a latent space: processing a predefined embedding that represents the latent dimension using the decoder neural network to generate multi-modal data, having a plurality of feature dimensions, that defines a predicted multi-modal data archetype corresponding to the latent dimension; and updating the values of the set of decoder parameters using gradients of an archetype loss function that measures an error between: (i) a predicted multi-modal data archetype corresponding to the latent dimension, and (ii) a target multi-modal data archetype corresponding to the latent dimension.